Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBITDA: 2020-2025

Historic EBITDA for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$38.7 million.

  • Lyell Immunopharma's EBITDA rose 10.88% to -$38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.2 million, marking a year-over-year decrease of 61.46%. This contributed to the annual value of -$342.6 million for FY2024, which is 50.84% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's EBITDA is -$38.7 million, which was up 9.54% from -$42.8 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's EBITDA registered a high of -$6.0 million during Q4 2022, and its lowest value of -$192.4 million during Q4 2024.
  • For the 3-year period, Lyell Immunopharma's EBITDA averaged around -$64.0 million, with its median value being -$51.8 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's EBITDA skyrocketed by 92.96% in 2022 and then tumbled by 764.05% in 2023.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's EBITDA stood at -$85.3 million in 2021, then soared by 92.96% to -$6.0 million in 2022, then plummeted by 764.05% to -$51.8 million in 2023, then crashed by 271.13% to -$192.4 million in 2024, then rose by 10.88% to -$38.7 million in 2025.
  • Its EBITDA was -$38.7 million in Q3 2025, compared to -$42.8 million in Q2 2025 and -$52.3 million in Q1 2025.